## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of treating lymphoma in a subject in need thereof, comprising:

administering by intravenous or intra-arterial injection to a subject afflicted with lymphoma an antibody that binds to tenascin in a treatment effective amount, wherein said antibody is coupled to a radioisotope.

2. (Original) A method according to claim 1, wherein said antibody is a monoclonal antibody.

3. (Original) A method according to claim 1, wherein said subject is a human

subject.

4. (Original) A method according to claim 1, wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6.

5. (Original) A method according to claim 1, wherein said lymphoma is Hodgkin's lymphoma.

6. (Original) A method according to claim 1, wherein said lymphoma is Non-Hodgkin's lymphoma.

7. (Canceled)

8. (Previously Presented) A method according to claim 1, wherein said radioisotope is selected from the group consisting of $^{131}1$, $^{90}Y$, $^{211}At$, $^{212}Bi$, $^{67}Cu$, $^{186}Re$, $^{188}Re$, and $^{112}Pb$.

9. (Previously Presented) A method according to claim 1, wherein said radioisotope is $^{131}1$.

10. (Previously Presented) A method according to claim 1, wherein said antibody coupled to a radioisotope is administered in an amount of from 10 mCi to 100 mCi.

11. (Cancelled)

12. (Currently amended) A method of treating Non-Hodgkin's lymphoma in a human subject in need thereof, comprising:

~~parenterally~~ administering by intravenous or intra-arterial injection to a human subject afflicted with lymphoma a monoclonal antibody that binds to tenascin in a treatment effective amount;

wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6; and wherein said antibody is coupled to a radioisotope.

13. (Original) A method according to claim 12, wherein said Non-Hodgkin's Lymphoma is unresponsive to chemotherapy treatment selected from the group consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment.

14. (Original) A method according to claim 12, wherein said Non-Hodgkin's Lymphoma is unresponsive to rituximab treatment.

15. (Original) A method according to claim 12, wherein said radioisotope is selected from the group consisting of $^{131}1$, $^{90}Y$, $^{211}At$, $^{212}Bi$, $^{67}Cu$, $^{186}Re$, $^{188}Re$, and $^{112}Pb$.

16. (Original) A method according to claim 12, wherein said radioisotope is $^{131}1$.

17. (Previously Presented) A method according to claim 12, wherein said antibody coupled to a radioisotope is administered in an amount of from 10 mCi to 100 mCi.

18. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is a low grade lymphoma.

19. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is an intermediate grade lymphoma.

20. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is a high grade lymphoma.

21. (Cancelled)

22. (Currently amended) A method of treating Non-Hodgkin's lymphoma in a human subject in need thereof, comprising:

~~parenterally~~ administering by intravenous or intra-arterial injection to a human subject afflicted with Non-Hodgkin's lymphoma monoclonal antibody 81C6 ~~monoclonal antibody~~ coupled to $^{131}1$ in an amount of from 10 mCi to 100 mCi, wherein the Non-Hodgkin's lymphoma is unresponsive to chemotherapy.

23. (Currently amended) A method of treating lymphoma in a human subject in need thereof, comprising:

administering ~~intravenously~~ by intravenous or intra-arterial injection to a subject afflicted with lymphoma an antibody that binds to tenascin in a treatment effective amount, wherein said antibody is coupled to a radioisotope and retention of said antibody in the lymphoma is at least two-fold greater compared to normal tissue.

24. (Previously presented) A method according to claim 12, wherein said antibody is a murine monoclonal antibody 81C6.

25. (New) A method according to claim 23, wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6.